Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Subcutaneous Heparin Leads to Rectus Sheath Hematoma: A Rare Complication.

Azharuddin M, Gupta M, Maniar M.

Cureus. 2018 Jun 8;10(6):e2769. doi: 10.7759/cureus.2769.

2.

Determination of Degradation Kinetics and Effect of Anion Exchange Resin on Dissolution of Novel Anticancer Drug Rigosertib in Acidic Conditions.

Patel HH, Maniar M, Ren C, Dave RH.

AAPS PharmSciTech. 2018 Jan;19(1):93-100. doi: 10.1208/s12249-017-0820-3. Epub 2017 Jun 9.

PMID:
28600665
3.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler AL, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA.

Ann Oncol. 2016 Jun;27(6):1180. doi: 10.1093/annonc/mdw095. Epub 2016 Mar 3. No abstract available.

PMID:
26945010
4.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Leichman L, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA.

Ann Oncol. 2015 Dec;26(12):2505. doi: 10.1093/annonc/mdv477. Epub 2015 Oct 21. No abstract available.

5.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Leichman L, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler AL, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA.

Ann Oncol. 2015 Sep;26(9):1923-9. doi: 10.1093/annonc/mdv264. Epub 2015 Jun 19. Erratum in: Ann Oncol. 2015 Dec;26(12):2505. Leichman, L [added]. Ann Oncol. 2016 Jun;27(6):1180.

6.

Acute renal infarction presenting with acute abdominal pain secondary to newly discovered atrial fibrillation: a case report and literature review.

Eltawansy SA, Patel S, Rao M, Hassanien S, Maniar M.

Case Rep Emerg Med. 2014;2014:981409. doi: 10.1155/2014/981409. Epub 2014 Dec 29.

7.

Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.

Silverman LR, Greenberg P, Raza A, Olnes MJ, Holland JF, Reddy P, Maniar M, Wilhelm F.

Hematol Oncol. 2015 Jun;33(2):57-66. doi: 10.1002/hon.2137. Epub 2014 Apr 29.

8.

Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.

Bowles DW, Diamond JR, Lam ET, Weekes CD, Astling DP, Anderson RT, Leong S, Gore L, Varella-Garcia M, Vogler BW, Keysar SB, Freas E, Aisner DL, Ren C, Tan AC, Wilhelm F, Maniar M, Eckhardt SG, Messersmith WA, Jimeno A.

Clin Cancer Res. 2014 Mar 15;20(6):1656-65. doi: 10.1158/1078-0432.CCR-13-2506. Epub 2014 Feb 3.

9.

Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer.

Ohnuma T, Lehrer D, Ren C, Cho SY, Maniar M, Silverman L, Sung M, Gretz HF 3rd, Benisovich V, Navada S, Akahoho E, Wilck E, Taft DR, Roboz J, Wilhelm F, Holland JF.

Am J Cancer Res. 2013 Jun 20;3(3):323-38. Print 2013.

10.

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.

Komrokji RS, Raza A, Lancet JE, Ren C, Taft D, Maniar M, Wilhelm F, List AF.

Br J Haematol. 2013 Aug;162(4):517-24. doi: 10.1111/bjh.12436. Epub 2013 Jun 21.

11.

Determination of intestinal permeability of rigosertib (ON 01910.Na, Estybon): correlation with systemic exposure.

White MP, Babayeva M, Taft DR, Maniar M.

J Pharm Pharmacol. 2013 Jul;65(7):960-9. doi: 10.1111/jphp.12057. Epub 2013 Mar 25.

PMID:
23738723
12.

Disposition of ON 01210.Na (Ex-RAD(R)), a novel radioprotectant, in the isolated perfused rat liver: probing metabolic inhibition to increase systemic exposure.

Tamhane M, Maniar M, Ren C, Benzeroual KE, Taft DR.

J Pharm Sci. 2013 Feb;102(2):732-40. doi: 10.1002/jps.23391. Epub 2012 Dec 4.

PMID:
23212688
13.

Amelioration of radiation-induced hematopoietic and gastrointestinal damage by Ex-RAD(R) in mice.

Ghosh SP, Kulkarni S, Perkins MW, Hieber K, Pessu RL, Gambles K, Maniar M, Kao TC, Seed TM, Kumar KS.

J Radiat Res. 2012 Jul;53(4):526-36. doi: 10.1093/jrr/rrs001. Epub 2012 Jun 6.

14.

Radioprotective effects of ON 01210.Na upon oral administration.

Suman S, Datta K, Doiron K, Ren C, Kumar R, Taft DR, Fornace AJ Jr, Maniar M.

J Radiat Res. 2012;53(3):368-76. Epub 2012 May 11.

15.

Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.

Olnes MJ, Shenoy A, Weinstein B, Pfannes L, Loeliger K, Tucker Z, Tian X, Kwak M, Wilhelm F, Yong AS, Maric I, Maniar M, Scheinberg P, Groopman J, Young NS, Sloand EM.

Leuk Res. 2012 Aug;36(8):982-9. doi: 10.1016/j.leukres.2012.04.002. Epub 2012 Apr 21.

16.

Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.

Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A.

Clin Cancer Res. 2012 Apr 1;18(7):2048-55. doi: 10.1158/1078-0432.CCR-11-2813. Epub 2012 Feb 14.

17.

Administration of ON 01210.Na after exposure to ionizing radiation protects bone marrow cells by attenuating DNA damage response.

Suman S, Maniar M, Fornace AJ Jr, Datta K.

Radiat Oncol. 2012 Jan 20;7:6. doi: 10.1186/1748-717X-7-6.

18.

Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species.

Chun AW, Freshwater RE, Taft DR, Gillum AM, Maniar M.

Biopharm Drug Dispos. 2011 Mar;32(2):99-111. doi: 10.1002/bdd.741. Epub 2011 Jan 14.

PMID:
21341279
19.

Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.

Chun AW, Cosenza SC, Taft DR, Maniar M.

Cancer Chemother Pharmacol. 2009 Dec;65(1):177-86. doi: 10.1007/s00280-009-1022-9. Epub 2009 May 24.

PMID:
19466411
20.

Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms.

Ghosh SP, Perkins MW, Hieber K, Kulkarni S, Kao TC, Reddy EP, Reddy MV, Maniar M, Seed T, Kumar KS.

Radiat Res. 2009 Feb;171(2):173-9. doi: 10.1667/RR1367.1.

PMID:
19267542
21.

Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.

Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, Hidalgo M, Baker SD, Donehower RC.

J Clin Oncol. 2008 Dec 1;26(34):5504-10. doi: 10.1200/JCO.2008.17.9788. Epub 2008 Oct 27.

22.

Development and validation of a sensitive liquid chromatographic method for the analysis of a novel radioprotectant: ON 01210.Na.

Fernandes PP, Maniar M, Dash AK.

J Pharm Biomed Anal. 2007 Apr 11;43(5):1796-803. Epub 2006 Dec 20.

PMID:
17184951
23.

Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB.

Margolis P, Hackbarth C, Lopez S, Maniar M, Wang W, Yuan Z, White R, Trias J.

Antimicrob Agents Chemother. 2001 Sep;45(9):2432-5.

24.

A fluorescence-based homogeneous assay for measuring activity of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase.

Wang W, Maniar M, Jain R, Jacobs J, Trias J, Yuan Z.

Anal Biochem. 2001 Mar;290(2):338-46.

PMID:
11237337
27.

Insect repellent formulations of N,N-diethyl-m-toluamide (deet) in a liposphere system: efficacy and skin uptake.

Domb AJ, Marlinsky A, Maniar M, Teomim L.

J Am Mosq Control Assoc. 1995 Mar;11(1):29-34.

PMID:
7616186
28.

Anesthetic activity of the lipospheres bupivacaine delivery system in the rat.

Hersh EV, Maniar M, Green M, Cooper SA.

Anesth Prog. 1992;39(6):197-200.

29.
30.

Determination of specific rate constants of specific oligomers during polyester hydrolysis.

Maniar ML, Kalonia DS, Simonelli AP.

J Pharm Sci. 1991 Aug;80(8):778-82.

PMID:
1791540
31.

Drug delivery to the brain using polymers.

Domb A, Maniar M, Bogdansky S, Chasin M.

Crit Rev Ther Drug Carrier Syst. 1991;8(1):1-17. Review.

PMID:
1868550
32.

Polyanhydrides. V. Branched polyanhydrides.

Maniar M, Xie XD, Domb AJ.

Biomaterials. 1990 Nov;11(9):690-4.

PMID:
2090304
33.

Supplemental Content

Loading ...
Support Center